Background
==========

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) was first described in 2010 by Pittock et al. \[[@B1]\] They described eight patients presenting with similar clinical and MRI-findings: sub-acute diplopia, gait ataxia and punctiform gadolinium enhancement "peppering" the pons. As distance from the pons increased, lesions became less numerous. Other accompanying clinical symptoms included dysartria, dysesthesia of the face and finally paraparesis and urine retention. The main manifestations of CLIPPERS are summarized in Table  [1](#T1){ref-type="table"}.

###### 

**Core features of CLIPPERS (adapted from Simon et al.)**\[[@B2]\]

                                     **Clinical:** 
  ------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             **-** subacute progressive ataxia and diplopia
                                 **Radiological:** 
                                             **-** numerous punctate or nodular enhancing lesions bilaterally within one of the three following anatomical locations: pons, brachium pontis (=middle cerebellar punducle), cerebellum
                                             **-** individual radiological lesions are small but may coalesce to form larger lesions
                                             **-** lesions may occur in the spinal cord, basal ganglia or cerebral white matter but should be decreasing density with increasing distance from the pons.
                **Corticosteroid responsiveness:** 
                                             **-** prompt and significant clinical and radiological response to corticosteroids
                            **Histopathological:** 
                                             **-** white matter perivascular lymphohistiocytic infiltrate with or without parenchymal extension.
                                             **-** infiltrate contains predominantly CD3 + and CD20+ lymphocytes.
                                             **-** absence of the following histopathological characteristics:
                                                     ○ monoclonal or atypical lymphocyte population
                                                     ○ necrotising granulomatomas or giant cells
                                                     ○ histological features of vasculitis
    **Differential diagnosis should be excluded:** 
                                             **-** CNS lymphoma, glioma, primary CNS vasculitis, paraneoplastic syndrome, sarcoidosis, demyelinating disease, Behcet's and Sjogren disease, tuberculosis, neurolues, Whipple's disease and histiocytosis.

Since 2010, several new possible cases have been published (Table  [2](#T2){ref-type="table"}). Despite extensive diagnostic work-up so far, the pathogenesis had not been elucidated. An immune-mediated process has been postulated on the basis of the establishment of T-cell predominant infiltrates of the affected brain lesions and radiologic resolution of the lesions upon immunosuppressive treatment.

###### 

Summary of published CLIPPERS case reports; initial- and follow up therapy

  **Author**                                                 **Cases**                                  **Biopsy**   **Initial treatment**   **Maintenance treatment**                              **Follow up (months)**   **Therapy stopped**   **Decline\*\*\***
  ---------------------------------------------------------- ------------------------------------------ ------------ ----------------------- ------------------------------------------------------ ------------------------ --------------------- -------------------
  Pittock et al. \[[@B1]\]                                   8                                          4            prednisone              1 patient: prednisone and methotrexate                 144                      no                    6/8
  1 patient: prednisone                                      25 (died)                                  no                                                                                                                                         
  1 patient: prednisone and azathioprine                     43                                         no                                                                                                                                         
  1 patient: prednisone and mitoxantrone                     14                                         no                                                                                                                                         
  4 patients: prednisone                                     20, 7, 22 and 7                            no                                                                                                                                         
  Simon et al. \[[@B2]\]                                     5                                          5            prednisone              1 patient: prednisone and methotrexate                 12                       no                    5/5
  2 patients: prednisone, azathioprine and cylophosphamide   36, 72                                     no                                                                                                                                         
  1 patient: prednisone, mycophenolate and cylophosphamide   64                                         no                                                                                                                                         
  1 patient: prednisone and cylophosphamide                  100                                        no                                                                                                                                         
  Taieb et al. \[[@B3]\]                                     1                                          1            prednisone              prednisone and rituximab                               9                        no                    unknown
  Jones et al. \[[@B4]\]                                     2\*                                        1\*          prednisone              prednisone                                             \> 6                     no                    1/1
  Sempere et al. \[[@B5]\]                                   1                                          \-           prednisone              prednisone and methotrexate                            6                        no                    unknown
  Duprez et al. \[[@B6]\]                                    1                                          \-           prednisone              unknown                                                \> 3                     unknown               unknown
  List et al. \[[@B7]\]                                      1                                          \-           prednisone              prednisone and methotrexate                            \> 3                     no                    unknown
  Limousin et al. \[[@B8]\]                                  1\*\*                                      1\*\*        \-                      \-                                                     \-                       \-                    \-
  Gabilondo et al. \[[@B9]\]                                 1                                          \-           prednisone              prednisone, immunoglobulins iv once and azathioprine   9                        no                    1/1
  Kastrup et al. \[[@B10]\]                                  3                                          3            2/3 prednisone          1 patient: prednisone and cyclophosphamide             17                       no                    3/3
  1 patient: prednisone                                      15                                         no                                                                                                                                         
  1/3 dexamethason                                           1 patient: dexamethason and methotrexate   9            no                                                                                                                            
  Biotti et al. \[[@B11]\]                                   1                                          \-           prednisone              prednisone and azathioprine                            7                        no                    unknown

\* in a 2^nd^ described case, biopsy was initiated after failed initial prednisone therapy. PA results showed a low grade astrocytoma.

\*\* this case report described a case in which biopsy was initiated after failed initial prednisone therapy. PA results showed a primary central nervous system lymphoma.

\*\*\* decline when maintenance treatment was tried to stopped.

All patients described so far (Table  [2](#T2){ref-type="table"}) were treated with intravenous and subsequent oral corticosteroids with gradually improvement of the clinical condition. Unfortunately, almost all patients relapsed following glucocorticoid tapering and required maintenance glucocorticoid or other immunosuppressive therapy. We present this new case of CLIPPERS to underline the importance of introducing maintenance immunosuppressive therapy after glucocorticoid treatment and the need to closely monitor for side effects during this prolonged therapy.

Case presentation
=================

A 63-year-old male presented with a five week history of double vision, rotational vertigo with tinnitus, progressive gait imbalance and apathy. One month earlier he had undergone tibia osteotomy surgery because of varus deformity. He used no medication. He had a history of alcohol abuse and did not smoke. He had no history of international traveling. There was no family history of neurological disease.

Except from postsurgical findings at his right knee general physical examination was normal. The blood pressure was 130/70 mmHg, pulse rate 78/minute, and he was afebrile. On initial neurological examination he was alert and cognitive functions were normal. His speech was dysarthric, chantering. Examination of the cranial nerves revealed a right abducens nerve paresis and an upbeat nystagmus. The pinprick sensation in the V3 distribution of the trigeminal nerve was symmetrically decreased. Other cranial nerve functions were normal. Strength was normal in muscles of the arms and legs and sensation was preserved. Vibration sense on both legs was diminished. The arms and legs on both sides showed atactic, dysmetric movements. Tendon reflexes were normal and the plantar reflexes were normal. He had an impressive gait ataxia and he was unable to walk without aid. His gait was further impaired due to the recent surgery.

As he was known with alcohol abuse, Wernicke's syndrome was firstly assumed and he was promptly treated with intravenous thiamine.

However, the neurological condition of the patient further deteriorated. He developed difficulties swallowing and became incontinent for urine. His gait ataxia worsened and a slight spastic paraparesis developed.

In this patient with progressive cranial nerve dysfunction with ocular signs, ataxia and pyramidal tract signs, brain stem dysfunction with a variety of causes should be considered. The broad differential diagnosis included CNS lymphoma, primary CNS vasculitis, demyelinating diseases, paraneoplastic syndromes, sarcoidosis, tuberculosis and neurolues. The diagnosis of Wernicke's syndrome was rejected as the clinical picture deteriorated and the pre-treatment thiamine level showed to be 118 nmol/L (normal range: 60--200 nmol/L).

MRI T2-weighted and fluid-attenuated inversion recovery (FLAIR) images of the brain demonstrated distinct hyperintensity abnormalities consisting of punctuate lesions in the pons, brachium pontis and cerebellum (Figure  [1](#F1){ref-type="fig"}A). The lesions were gadolinium enhancing but had no significant mass effect.

![**Coronal FLAIR MRI images. A.** demonstrates the characteristic punctuate hyperintens lesions of the pons. **B.** shows diminishing of the pons-hyperintensity after glucocorticoid administration. The lesions were enhancing after gadolinium administration on T1 weighted images (not shown).](1471-2377-13-49-1){#F1}

Blood levels of C-reactive protein, ESR, Vit B12 and Angiotensine Converting Enzyme levels were normal. Liver parameters were normal except for a slightly elevated gamma-GT of 65 U/L (reference \<55 U/L). Thyroid functions were normal.

Antinuclear antibodies, double-stranded DNA antibodies, extractable nuclear antigens, antineutrophil cytoplasmic antibodies and antineuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-Tr, anti-amphiphysine, anti-CV2 and anti-Ma2) were not detected.

Serologic tests on Syphilis, HIV, Borrelia Burgdorferi, anti-DNase B and anti-streptolysine titer were negative. Auramine staining and PCR for M.tuberculosis complex DNA were negative.

Analysis of the cerebrospinal fluid showed a raised protein level (protein 1.3 g/L, reference range 0.2--0.5) and a slight pleiocytosis (6,0 E06, reference \<5 E06). Red cell count and glucose levels were normal. The IgG index was marginally increased (0.62, reference range 0.3--0.6), no oligoclonal bands were found. Cytology study reports showed normal amounts of lymphocytes, granulocytes monocytes and erythrocytes. Malignant cells were not detected.

Cultures of urine, blood and cerebral spine fluid were all negative.

MRI of the spinal cord and CT scanning of the chest, abdomen and pelvis showed no abnormalities. Total body PET CT scanning was negative for malignancies.

On the base of the typical MRI findings and exclusion of other possible diagnoses the diagnosis of CLIPPERS was presumed. The patient was treated with 1000 mg intravenous methylprednisolone daily for a period of three days, followed by oral prednisolone 80 mg per day. Within a week from starting treatment the symptoms gradually improved and on MRI two weeks from starting treatment the pontine lesions decreased in number and intensity (Figure  [1](#F1){ref-type="fig"}B).

Maintenance immunosupressive therapy by oral prednisolone 80 mg per day was continued, adding methotrexate 2.5 mg weekly to the regimen as long-lasting immunosuppressive therapy was probably needed.

However, the therapy was complicated in several ways. Firstly, by the end of the first month of therapy our patient developed diabetes mellitus and deep venous thrombosis. Subsequently, severe liver function abnormalities developed after methotrexate was started (Table  [3](#T3){ref-type="table"}). Therefore, this drug was substituted by azathioprine in a step up dosage regimen up to 100 mg daily. Hereafter, a severe and long-lasting pancytopenia developed (Table  [3](#T3){ref-type="table"}). Bone marrow analysis showed hyperplastic erythropoiesis and hypoplastic granulopoiesis compatible with a side effect of the immunosuppressive therapy. The azathioprine was therefore stopped and prednisone 20 mg per day was continued.

###### 

Laboratory results before and after treatment with immunosupressive therapy

  **Liver function results on admission**   **Liver function results after treatment with methotrexate**   **Reference range**   
  ----------------------------------------- -------------------------------------------------------------- --------------------- ------------
  ASAT                                      20 U/l                                                         97 U/l                \< 35
  ALAT                                      18 U/l                                                         172 U/l               \< 45
  Alkaline phosphatase                      105 U/l                                                        82 U/l                \< 120
  Bilirubin                                 9 umol/l                                                       14 umol/l             \<17
  Gamma GT                                  65 U/l                                                         394 U/l               \< 55
  **Hematologic results on admission**      **Hematologic results after treatment with azathioprine**      **Reference range**   
  Leucocytes                                7,9 E09/l                                                      1,5 E09/l             4,0--10,0
  Erythrocytes                              4,54 E12/l                                                     1,96 E12/l            4,50--5,50
  Hemaglobin                                8,6 mmol/l                                                     3,9 mmol/l            8,5--11,0
  Hematocrit                                0,42 l/l                                                       0,18 l/l              0,40--0,50
  Thrombocytes                              229 E09/l                                                      9 E09/l               150--400

After recovering from the pancytopenia, mycofenolaatmofetil was added starting at 500 mg daily and in increased dosage to 1000 mg bid. During this whole episode prednisone treatment was maintained at a dosage of 20 mg daily. A severe intercurrent herpes infection was treated with intravenous valcyclovir.

After a course of 18 months, our patient has not had any relapse of his neurological deficits. There were no cranial nerve deficits, no pareses and his gait was normal.

Discussion
----------

We made the diagnosis of CLIPPERS combining the clinical and typical MRI findings only after exclusion of other possible diagnoses. We choose not to perform a biopsy because of the localization of the abnormalities and because the imaging results and clinical presentation were very similar to the patients described by Pittock et al. \[[@B1]\].

In most of previously published studies it was mentioned that discontinuation of steroid treatment led to a clinical relapse (Table  [2](#T2){ref-type="table"}). Mean follow up time of all published reports so far was 28 months (3--144 months), and no successful steroid discontinuation was reported.

It is known that induction of remission by using glucocorticosteroids followed by maintenance glucocorticosteroid combining other immunosuppressive therapy in autoimmune diseases such as vasculitides should be continued for at least 2--5 years \[[@B12],[@B13]\]. Since CLIPPERS has comparable pathologic features as in vasculitides consisting of perivascular lymphocytic infiltrate, it seems likely that tapering of maintenance therapy should be proposed only after 2--5 years of treatment guided by clinical monitoring and follow up MRI.

Finally we emphasize that in clinical practice one must pay attention to the adverse events, as described in our case. We recommend tapering immunosuppressive therapy in conjunction with frequent clinical monitoring and imaging, thus enabling us to treat any further relapse on time. Our findings support the need for further follow up studies to determine the duration of treatment.

Conclusion
==========

CLIPPERS presents with distinctive clinical and MRI-findings and can be diagnosed after exclusion other differential diagnoses \[[@B1],[@B3]\]. Our patient confirmed the appropriateness of the initiation of treatment without histopathological confirmation.

A favourable clinical response to corticoid treatment lends further support to the diagnosis of CLIPPERS. We stress that careful clinical and laboratory monitoring is warranted because of the side effects of longstanding glucocorticosteroid and additional immunosuppressive therapy. Follow-up studies to determine the duration of treatment are necessary.
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